NODE (groiN ultrasOunD cancEr)
This study is an open label, prospective, experimental, randomised clinical trial. The primary aim of this study is to determine whether it is feasible to randomise vulvar cancer patients into one of two treatment arms:1) surgical groin node dissection (as delivered though either a sentinel node biopsy or inguinofemoral lymph node dissection (IFL), or 2) serial high-resolution bilateral groin ultrasound surveillance and clinical examination every 2 months.
- EligibilityCriteria: Inclusion Criteria:  Women, over 18 years, with histologically confirmed SCC, adenocarcinoma or melanoma of the vulva Clinically stage I or II on medical imaging (CT scan of pelvis, abdomen, and chest), without evidence of regional or distant metastatic disease Participant must be suitable to undergo IFL/SNB according to local clinical practice management guidelines Signed written informed consent Negative serum pregnancy test ≤ 30 days of surgery in pre-menopausal women and women < 2 years after the onset of menopause Patient lives within 40 km of a medical diagnostic imaging centre (site investigator approval required for special circumstances)  Exclusion Criteria:  Women with non-invasive vulvar conditions (e.g. non-invasive non-mammary Paget's disease) Squamous cell carcinoma (SCC) of the vulva with depth of invasion ≤1 mm Clinical or medical imaging evidence of regional and/or distant metastatic disease Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator) Other prior malignancies <5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma in situ Estimated life expectancy of ≤6 months - HealthyVolunteers: No - Gender: Female - GenderBased: Yes - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult